HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm T Van Gorp, I Cadron, E Despierre, A Daemen, K Leunen, F Amant, ... British journal of cancer 104 (5), 863-870, 2011 | 433 | 2011 |
Endometriosis and the development of malignant tumours of the pelvis. A review of literature T Van Gorp, F Amant, P Neven, I Vergote, P Moerman Best practice & research Clinical obstetrics & gynaecology 18 (2), 349-371, 2004 | 414 | 2004 |
Ovarian cancer N Colombo, T Van Gorp, G Parma, F Amant, G Gatta, C Sessa, I Vergote Critical reviews in oncology/hematology 60 (2), 159-179, 2006 | 391 | 2006 |
Management of borderline ovarian neoplasms I Cadron, K Leunen, T Van Gorp, F Amant, P Neven, I Vergote Journal of clinical oncology 25 (20), 2928-2937, 2007 | 305 | 2007 |
Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis EMJ Meys, J Kaijser, R Kruitwagen, BFM Slangen, B Van Calster, ... European Journal of Cancer 58, 17-29, 2016 | 270 | 2016 |
Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients IJG Rutten, DPJ van Dijk, RFPM Kruitwagen, RGH Beets‐Tan, ... Journal of cachexia, sarcopenia and muscle 7 (4), 458-466, 2016 | 198 | 2016 |
Lymph node metastasis in stages I and II ovarian cancer: a review M Kleppe, T Wang, T Van Gorp, BFM Slangen, AJ Kruse, R Kruitwagen Gynecologic oncology 123 (3), 610-614, 2011 | 191 | 2011 |
Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer IJG Rutten, J Ubachs, RFPM Kruitwagen, RGH Beets‐Tan, ... Journal of cachexia, sarcopenia and muscle 8 (4), 630-638, 2017 | 182 | 2017 |
A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) BJ Monk, C Parkinson, MC Lim, DM O'malley, A Oaknin, MK Wilson, ... Journal of Clinical Oncology 40 (34), 3952-3964, 2022 | 178 | 2022 |
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant … T Van Gorp, J Veldman, B Van Calster, I Cadron, K Leunen, F Amant, ... European Journal of Cancer 48 (11), 1649-1656, 2012 | 153 | 2012 |
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance—a study of the OVCAD consortium E Obermayr, DC Castillo-Tong, D Pils, P Speiser, I Braicu, T Van Gorp, ... Gynecologic oncology 128 (1), 15-21, 2013 | 146 | 2013 |
Sarcopenia and ovarian cancer survival: a systematic review and meta‐analysis J Ubachs, J Ziemons, IJG Minis‐Rutten, RFPM Kruitwagen, J Kleijnen, ... Journal of cachexia, sarcopenia and muscle 10 (6), 1165-1174, 2019 | 143 | 2019 |
Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial MJ Rutten, HS Van Meurs, R Van De Vrie, KN Gaarenstroom, ... Journal of Clinical Oncology 35 (6), 613-621, 2017 | 142 | 2017 |
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA–IV: analysis of the OVCAD data S Polterauer, I Vergote, N Concin, I Braicu, R Chekerov, S Mahner, ... International Journal of Gynecologic Cancer 22 (3), 2012 | 134 | 2012 |
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma—analysis of patient data in the … G Hofstetter, N Concin, I Braicu, R Chekerov, J Sehouli, I Cadron, ... Gynecologic oncology 131 (1), 15-20, 2013 | 131 | 2013 |
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive B Van Calster, I Vanden Bempt, M Drijkoningen, N Pochet, J Cheng, ... Breast cancer research and treatment 113, 181-187, 2009 | 126 | 2009 |
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study UA Matulonis, D Lorusso, A Oaknin, S Pignata, A Dean, H Denys, ... Journal of clinical oncology 41 (13), 2436-2445, 2023 | 124 | 2023 |
Timing of debulking surgery in advanced ovarian cancer I Vergote, T Van Gorp, F Amant, K Leunen, P Neven, P Berteloot International Journal of Gynecologic Cancer 18 (Suppl 1), 2008 | 122 | 2008 |
Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods EMJ Meys, LS Jeelof, NMJ Achten, BFM Slangen, S Lambrechts, ... Ultrasound in Obstetrics & Gynecology 49 (6), 784-792, 2017 | 118 | 2017 |
The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery IJG Rutten, J Ubachs, RFPM Kruitwagen, DPJ van Dijk, RGH Beets-Tan, ... European Journal of Surgical Oncology (EJSO) 43 (4), 717-724, 2017 | 109 | 2017 |